diclofenac has been researched along with Central Nervous System Origin Vertigo in 4 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile." | 9.12 | Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. ( Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE, 2007) |
| "The efficacy and tolerability of aceclofenac (100 mg bid; n = 109), a new non-steroidal anti-inflammatory agent, was compared to that of indomethacin (50 mg bid; n = 110) in a multi-centre, 12-week, randomized, double-blind clinical trial in patients with rheumatoid arthritis." | 9.08 | The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. ( Bowdler, J; Kornasoff, D; Maisenbacher, J; Raber, A, 1996) |
| "Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile." | 5.12 | Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. ( Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE, 2007) |
| "The efficacy and tolerability of aceclofenac (100 mg bid; n = 109), a new non-steroidal anti-inflammatory agent, was compared to that of indomethacin (50 mg bid; n = 110) in a multi-centre, 12-week, randomized, double-blind clinical trial in patients with rheumatoid arthritis." | 5.08 | The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. ( Bowdler, J; Kornasoff, D; Maisenbacher, J; Raber, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ault, J | 1 |
| Willburger, RE | 1 |
| Mysler, E | 1 |
| Derbot, J | 1 |
| Jung, T | 1 |
| Thurston, H | 1 |
| Kreiss, A | 1 |
| Litschig, S | 1 |
| Krammer, G | 1 |
| Tate, GA | 1 |
| Kornasoff, D | 1 |
| Maisenbacher, J | 1 |
| Bowdler, J | 1 |
| Raber, A | 1 |
| Tausch, G | 1 |
| Eberl, R | 1 |
| Tuschl, P | 1 |
3 trials available for diclofenac and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Topics: Abdominal Pain; Acute Disease; Administration, Oral; Adult; Aged; Analysis of Variance; Argentina; D | 2007 |
The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis.
Topics: Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; El | 1996 |
[Clinical experiences and results of clinical experimental studies with Voltaren in rheumatic diseases].
Topics: Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Diclofenac; DNA Repair; Drug Evalu | 1976 |
1 other study available for diclofenac and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Teaching case: migraine and pupil dilation.
Topics: Adult; Anticonvulsants; Comorbidity; Cyclooxygenase Inhibitors; Diclofenac; Female; Fructose; Humans | 2011 |